Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Moves Real-World Evidence Paradigm Forward With Draft Guidance

Executive Summary

The US agency has followed its public enthusiasm for increasing the use of real-world evidence to support pre-market and post-market device decisions with a draft guidance mapping out a strategy for doing so.

Advertisement

Related Content

Applying Real-World Device Data: US FDA Finalizes Its Thoughts
Real World Evidence Is Critical To Pharma’s Future: Can We Agree On What It Is?
Industry, US FDA Strike $1Bn Deal After Contentious User-Fee Negotiations
Shuren: FDA Willing to Kick-Start Device Evaluation Program, But Funding Guarantee Needed

Topics

Advertisement
UsernamePublicRestriction

Register

MT103657

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel